Free Trial
→ A new rule goes live in July — and the banks are quietly cashing in (From American Alternative) (Ad)
NASDAQ:COCP

Cocrystal Pharma 5/15/2025 Earnings Report

Cocrystal Pharma logo
$1.63 0.00 (0.00%)
Closing price 06/6/2025 03:58 PM Eastern
Extended Trading
$1.68 +0.05 (+2.76%)
As of 06/6/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Cocrystal Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.29
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Date
5/15/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Earnings Headlines

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
June 6 at 6:39 PM | finance.yahoo.com
Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
June 5 at 8:00 AM | globenewswire.com
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
June 8, 2025 | American Alternative (Ad)
Zacks Small Cap Has Strong Estimate for COCP FY2025 Earnings
May 31, 2025 | americanbankingnews.com
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
May 29, 2025 | globenewswire.com
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
May 28, 2025 | finance.yahoo.com
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP), a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

View Cocrystal Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles